{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:50:48Z","timestamp":1787964648429,"version":"build-2784847793"},"reference-count":45,"publisher":"Informa UK Limited","issue":"sup15","funder":[{"name":"Symbio, and personal"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.2217\/fon-2017-0156","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T08:34:23Z","timestamp":1494318863000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10"],"prefix":"10.1080","volume":"13","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[{"name":"Department of Hematology, Tokai Central Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Pierre-Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Chan","family":"Kwon","sequence":"additional","affiliation":[{"name":"CELLTRION Healthcare Co. Ltd, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Yoon","sequence":"additional","affiliation":[{"name":"CELLTRION Healthcare Co. Ltd, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf"},{"key":"e_1_3_2_4_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500167838.pdf"},{"key":"e_1_3_2_5_1","unstructured":"U.S. Food & Drug Administration\n. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. www.fda.gov\/downloads\/drugs\/guidances\/ucm291134.pdf"},{"key":"e_1_3_2_6_1","unstructured":"U.S. Food & Drug Administration\n. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf"},{"key":"e_1_3_2_7_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf"},{"key":"e_1_3_2_8_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf"},{"key":"e_1_3_2_9_1","unstructured":"European Medicines Agency\n. Concept paper on extrapolation of efficacy and safety in medicine development. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129285.pdf"},{"key":"e_1_3_2_10_1","unstructured":"European Medicines Agency\n. Committee for Medicinal Products for Human Use. Assessment report for Truxima (procedure No. EMEA\/H\/C\/004112\/0000). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004112\/WC500222695.pdf"},{"issue":"15","key":"e_1_3_2_11_1","first-page":"1","article-title":"An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements","volume":"13","author":"Buske C","year":"2017","unstructured":"Buske C , OguraM, KwonH-C, YoonSW. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol.13(S15), 1\u20133 (2017).","journal-title":"Future Oncol."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209540"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1807.1807"},{"issue":"10","key":"e_1_3_2_14_1","first-page":"2038","article-title":"Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks","volume":"68","author":"Suh C-H","year":"2016","unstructured":"Suh C-H , Berrocal KasayA, Chalouhi El-KhouriEet al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol.68(Suppl. 10), 2038\u20132040 (2016).","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"e_1_3_2_15_1","first-page":"1635","article-title":"Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks","volume":"68","author":"Yoo D-H","year":"2016","unstructured":"Yoo D-H , MajstorovicL, KasayAet al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol.68(Suppl. 10), 1635 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_16_1","first-page":"S663","article-title":"Impact of anti-drug antibody on efficacy and safety over week 24 in both CT-P10 and innovator rituximab treatment groups","volume":"66","author":"Yoo D-H","year":"2014","unstructured":"Yoo D-H , ParkW, SlawomirJet al. Impact of anti-drug antibody on efficacy and safety over week 24 in both CT-P10 and innovator rituximab treatment groups. Arthritis Rheumatol.66, S663\u2013S664 (2014).","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"e_1_3_2_17_1","first-page":"1675","article-title":"Efficacy and safety of switched CT-P10 from innovator rituximab compared with those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks","volume":"67","author":"Yoo D-H","year":"2015","unstructured":"Yoo D-H , ParkW, SuhC-Het al. Efficacy and safety of switched CT-P10 from innovator rituximab compared with those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks. Arthritis Rheumatol.67(Suppl. 10), 1675 (2015).","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"e_1_3_2_18_1","first-page":"2058","article-title":"Efficacy and safety of rituximab biosimilar candidate (CT- P10) and innovator rituximab in patients with rheumatoid arthritis: results from Phase I randomized controlled trial over 72 weeks","volume":"67","author":"Yoo D-H","year":"2015","unstructured":"Yoo D-H , ParkW, SuhC-H. Efficacy and safety of rituximab biosimilar candidate (CT- P10) and innovator rituximab in patients with rheumatoid arthritis: results from Phase I randomized controlled trial over 72 weeks. Arthritis Rheumatol.67(Suppl. 10), 2058 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S41645"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/681678"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075027"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042321"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.584.584"},{"issue":"6","key":"e_1_3_2_26_1","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross P","year":"2012","unstructured":"Boross P , LeusenJHW. Mechanisms of action of CD20 antibodies. Am. J. Cancer Res.2(6), 676\u2013690 (2012).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.1.10789"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1761"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"issue":"2","key":"e_1_3_2_30_1","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes","volume":"91","author":"Golay J","year":"2006","unstructured":"Golay J , CitteraE, Di GaetanoNet al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica91(2), 176\u2013183 (2006).","journal-title":"Haematologica"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.3.1581"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040119"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1352"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.012"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S8151"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S61292"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2862"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202435"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272765"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431825"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2013.2333"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210365"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1314"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.264.65.1"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1234"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:43Z","timestamp":1719125083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":45,"journal-issue":{"issue":"sup15","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.2217\/fon-2017-0156"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0156","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}